DURECT Corporation (DRRX)

Market Cap	59.31M
Revenue (ttm)	1.66M -21.6%
Net Income	-3.48M
EPS	-0.12
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	1.930
Day's Range	n/a
52-Week Range	0.480 - 2.640
Beta	0.93
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2025

About DRRX

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company’s lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis. The company also offers POSIMIR, a post-surgical pain product to deliver bupivacain...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 28, 2000
• Employees: 21
• Stock Exchange: NASDAQ
• Ticker Symbol: DRRX
• Website: https://www.durect.com

Financial Performance

In 2024, DURECT's revenue was $2.03 million, a decrease of -21.58% compared to the previous year's $2.59 million. Losses were -$8.32 million, -69.87% less than in 2023.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jan 1, 2000

Data Sources Report a data error